Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trugman

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
Cephalalgia : an International Journal of Headache|September 21, 2019
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adultsPeter J Goadsby, Stewart J Tepper, Paul B Watkins, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Headache|July 3, 2026
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension studyDale S Bond, Jonathan H Smith, Alexandra Sinclair, et al.
The Journal of Physical Chemistry. A|August 7, 2008
Ultrafast spectroscopy of the uranium(IV) and thorium(IV) bis(ketimide) complexes (C5Me5)2An[-N=C(Ph)(CH2Ph)]2 (An = Th, U)David J Hilton, Rohit P Prasankumar, Eric J Schelter, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Neurology. Clinical Practice|October 14, 2024
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening PeriodTodd J Schwedt, Richard B Lipton, Peter J Goadsby, et al.
American Journal of Human Genetics|January 1, 1991
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindredD J Kwiatkowski, T G Nygaard, D E Schuback, et al.
Cephalalgia : an International Journal of Headache|September 15, 2021
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trialTodd J Schwedt, Richard B Lipton, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
Cephalalgia : an International Journal of Headache|September 21, 2019
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adultsPeter J Goadsby, Stewart J Tepper, Paul B Watkins, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Headache|July 3, 2026
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension studyDale S Bond, Jonathan H Smith, Alexandra Sinclair, et al.
The Journal of Physical Chemistry. A|August 7, 2008
Ultrafast spectroscopy of the uranium(IV) and thorium(IV) bis(ketimide) complexes (C5Me5)2An[-N=C(Ph)(CH2Ph)]2 (An = Th, U)David J Hilton, Rohit P Prasankumar, Eric J Schelter, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Neurology. Clinical Practice|October 14, 2024
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening PeriodTodd J Schwedt, Richard B Lipton, Peter J Goadsby, et al.
American Journal of Human Genetics|January 1, 1991
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindredD J Kwiatkowski, T G Nygaard, D E Schuback, et al.
Cephalalgia : an International Journal of Headache|September 15, 2021
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trialTodd J Schwedt, Richard B Lipton, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Pageof 21